Study of the Effect of Atorvastatin for Reducing "Inflamaging" (Aging-related Complication) in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen

Trial Profile

Study of the Effect of Atorvastatin for Reducing "Inflamaging" (Aging-related Complication) in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Atorvastatin (Primary) ; Raltegravir (Primary) ; Atazanavir; Darunavir; Fosamprenavir; Indinavir; Lopinavir; Ritonavir; Saquinavir; Tipranavir
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Acronyms RALATOR
  • Most Recent Events

    • 04 Oct 2017 Planned End Date changed from 1 May 2018 to 31 Aug 2018.
    • 04 Oct 2017 Planned primary completion date changed from 1 May 2018 to 31 Aug 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top